Diese Präsentation wurde erfolgreich gemeldet.
Die SlideShare-Präsentation wird heruntergeladen. ×

Most emerging biotech companies to watch.pdf

Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
VOL-10
|
ISSUE-02
|
2022
www.insightssuccess.com
The 10
Companies
ToWatchin2022
Most
Emerging
Emerging
Emerging
Biotech
En...
Way to save the life of every individual.
The cure to life
is Biotechnology
Embarking on
the Prospects
to Foster
Bio-Innovations
Editor’s Desk
Abhishek Joshi
Abhishek Joshi
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Wird geladen in …3
×

Hier ansehen

1 von 48 Anzeige

Weitere Verwandte Inhalte

Weitere von InsightsSuccess4 (20)

Aktuellste (20)

Anzeige

Most emerging biotech companies to watch.pdf

  1. 1. VOL-10 | ISSUE-02 | 2022 www.insightssuccess.com The 10 Companies ToWatchin2022 Most Emerging Emerging Emerging Biotech Engineering Biology to Solve Societal Challenges Evozyne Jeff Aronin, Chairman Evozyne
  2. 2. Way to save the life of every individual. The cure to life is Biotechnology
  3. 3. Embarking on the Prospects to Foster Bio-Innovations Editor’s Desk Abhishek Joshi Abhishek Joshi
  4. 4. iotechnology has become a major engine for Bnational and urban competitiveness in the twenty- first century. Biotechnology is being explored as a crucial development for future advancements and growing competition for policymakers. It has always been a knowledge-driven sector because of its consistency in comprehensively working to create value, decoding genomics and proteomics and being a paradigmatic knowledge-based economic activity. Biotechnology industries are also among the most innovative and important economic drivers in the modern business world. However, the biotechnology market has raised expectations among investors, workers, and consumers. This is partly related to the COVID-19 pandemic, which motivated the acceleration in investments in the sector so commonly characterized by its long-term results. Biotech industry trends have revolved around diversifying the production of patents and investing a lot of capital without expecting short and mid-term results—a typical script regarding the sector that could hold onto investors. Eventually, this requires considering how they can scale up and what is required, in order to deliver on their promise of providing innovative medicines to patients. Early in the life cycle, a biotech company's management team typically grows the business through a few core assets and limited programmers, focusing its resources where the most value can be gained, such as differentiation in manufacturing, understanding of disease and biology, or drug chemistry. One of the important aspects that have been significantly contributing to core drivers of longer-term success is building a portfolio of products to sustain growth – this research seeks to identify which portfolio approaches have enabled biotech to scale its progress, stimulate innovation for patients and created financial success for investors and founders. To further succeed in the niche, emerging companies try to create an "end-to-end" entity from research and development to commercialization, bringing their product(s) to market themselves. Moreover, ensuring the R&D profile continues to be the focus of most other biotech companies' attention remains a primary aim for these biotech companies. Among those who are R&D-focused, some adopt a "diversify approach," resulting in a significant increase in the number of assets across multiple therapeutic areas and relying heavily on revenue generated through collaboration agreements to advance assets past pre-clinical and Phase 1 stages. Embracing the ascending odyssey of the starlets that are enabling transformations in the biotech industry, Insights Success features the triumph trail of "The 10 Most Emerging Biotech Companies to Watch in 2022.” Flip through the pages and read on to comprehend the immersive advancements that are being driven by a vision to empower limitless ennoblements in the global healthcare industry. Have a Delightful Read!
  5. 5. Cover Story 08 16 20 Engineering Biology to Solve Societal Challenges Evozyne 26 Evozyne
  6. 6. 22 28 Golden Helex Providing Leading Genomic Data Analysis Software 32 36 38 40
  7. 7. sales@insightssuccess.com October, 2022 Editor-in-Chief Senior Sales Manager Business Development Manager Marketing Manager Technical Head Technical Specialist Digital Marketing Manager Research Analyst Database Management Technology Consultant Marry D'Souza Managing Editor Executive Editor Assistant Editors Visualizer David King Art & Design Director Associate Designer Kshitij S Peter Collins John Matthew Sales Executives David, Martin Business Development Executives Steve, Joe Jacob Smile Amar Sawant Dominique T. SME-SMO Executive Renuka Kulkarni Frank Adams Circulation Manager Robert Brown Stella Andrew David Stokes Copyright © 2022 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success. Reprint rights remain solely with Insights Success. Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess We are also available on : Abhishek Joshi Revati Badkas Jenny Fernandes Anish Miller Sandeep Tikode
  8. 8. Brief Company Name 3Scan is turning tissue biology and histopathology into data science, giving researchers the insights they need to break new ground. Featured Person Todd Hulman, CEO & Co-founder 3Scan 3scan.com ClinCapture is revolutionizing the clinical trial industry with Virtual Data Capture® and is the only provider of VDC®, a leading-edge suite of products designed to expedite remote and decentralized clinical trials. Scott Weidley, President & CEO ClinCapture c lincapture.com CMIC is an innovative and unique provider of high-quality solutions for the healthcare industry. We create value by accelerating the access to therapies that improve patients’ lives. Jenny Lin, COO & Board of Director CMIC Inc en.cmicgroup.com Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. Jeff Aronin, Chairman Evozyne evozyne.com Golden Helix has been delivering industry-leading bioinformatics solutions for over 20 years with 1,000s of users around the world. Andreas Scherer, President & CEO Golden Helixh goldenhelix.com Janrain is the first choice of global enterprises for mission- critical customer identity and access management (CIAM) needs. Jim Kaskade, CEO Janrain janrain.com Metrendalytics Consulting, focused on helping companies develop highly customized and flexible business intelligence solutions. Jan Miotto, President Metrendalytics metrendalytics.com The organization aims to deliver excellent clinical development services and innovative resourcing solutions that let our clients complete their clinical trials in an efficient and cost-effective manner. Sharon Hilton, COO & Kristy Nichols, CEO Peachtree BioResearch Solutions peachtreebrs.com Triox Nano Ltd(Israel) is an innovative bio-technology company developing programmable biologic nano carriers that are able to accurately deliver payloads to their target. Roy Farfara, Founder & CTO Triox Nano The 10 Companies ToWatchin2022 Most Emerging Emerging Emerging Biotech Biotech Biotech
  9. 9. Engineering Biology to Solve Societal Challenges C o v e r S t o r y If nature is the world's best engineer, imagine what it can do if it's fast-forwarded by a few million years. Evozyne -Jeff Aronin, Chairman, Evozyne
  10. 10. echnical advancements in genetics and Tsupercomputing are driving an astonishing amount of scientific progress, colloquially known as the biology revolution. The advances come at a fortuitous time. Environmental threats are chipping away at the quality of life for millions, while new viral illnesses continue to emerge and thousands of known diseases lack effective treatments. Evozyne, founded by Paragon Biosciences, was created on the premise that the new-found ability to create high- performance proteins can deliver solutions to the some of most intractable modern problems. The company believes that by learning from evolution, it is possible to engineer future-proofed interventions for patients and address environmental challenges in carbon capture and energy storage. To learn more about its biology-based advancements, we at Insights Success crossed paths with Evozyne's team, and in the following interview, the company outlines its pathbreaking vision to benefit humanity. Below are the highlights of the interview. What was the initial idea behind the inception of Evozyne? Evozyne was founded by Paragon Biosciences to advance boundary-breaking biology from the laboratory and into the real world, where it can solve complex problems. Believing that the engineered proteins will dramatically accelerate scientific breakthroughs, in two years we recruited a world-class team of nearly 100 computational scientists, researchers, and commercial leaders to conduct a series of validation projects from Evozyne's new 30,000- square-foot lab in Chicago. Evozyne's evolution-based design is about encapsulating vital information from the evolutionary history of a protein into a computationally defined latent space that enables rational design of natural-like proteins. When combined with an iterative design-build-test approach, the models generate protein designs that far exceed performance of natural proteins and can be deployed in in real-world applications. In an early project, Evozyne partnered with Takeda, the Japanese pharmaceutical company, to improve the therapeutic potential of a specific target to treat a severe genetic disease. This inherited disorder causes a dangerous build-up of phenylalanine when a person eats protein or foods containing aspartame, which severely alters their quality of life. Evozyne delivered an engineered enzyme that greatly exceeded Takeda's design specifications, which led to an initial multi-asset licensing agreement worth up to $400 million plus potential royalties from any commercial product resulting from the collaboration. Our technology outperformed expectations in this critical test and resulted in an important collaboration for both companies. We are hopeful this partnership with Takeda will lead to new treatments that significantly improve the quality of life for patients. What are the primary objectives and philosophy of Evozyne? We believe boundary-breaking biology is the key to transformational applications in therapeutics and sustainability. Understanding that nature is the original and best engineer, we use deep evolutionary learning in the lab to understand millions of years of evolution. By using evolution-based design, we're able to tackle some of society's biggest challenges, like finding treatments for patients with untreated diseases and developing solutions for sustainability concerns. Philosophically, we are highly pragmatic and our design- build-test approach is applied to every aspect of our work. We partner with like-minded entities, working together to find world-changing solutions. To realize the impact and potential of our engineered proteins, we need partners who share our vision for a better world and a commitment to the breakthrough approaches required to get there. Our next-generation proteins can be tailored across functions, and our efficient design-build-test cycles enable commercial-scale solutions that unlock new products and IP for our partners. What are your key offerings that have a foothold in the industry? Evozyne began by combining artificial intelligence, specifically machine learning, with applied biology to accelerate scientific discovery. The process speeds up lead identification for new medicines, which can result in findings that support investigational new drug applications and biologic license applications for experimental The 10 Most Emerging Biotech Companies To Watch in 2022
  11. 11. therapeutics. From a timeline point of view, Evozyne works from the earliest points, identifying and optimizing lead targets, and continues its work through developing experimental therapeutics and supporting them through Phase 3 clinical trials. Currently, we are creating high-performance enzymes for our partners at Takeda and developing antibody, gene optimization, and CRISPR technology platforms that we believe will lead to the development of breakthrough therapeutics for patients. On the sustainability side, protein engineering moves the science beyond traditional chemical catalysts by developing enzymes that can withstand industrial conditions, functioning in high-temperature conditions, and overcoming pH resistance. Our lead sustainability candidate is engineered to perform at temperatures above 260 degrees Fahrenheit in an industrial setting. Until now, no enzyme has been able to function in the conditions associated with power generation. Our tests indicate that we have a product that meets the challenge of enzymatic on-site carbon capture, which means if successful the CO from power generation is never 2 released into the atmosphere. We look forward to proving its performance, first at the University of Kentucky this year and later at the National Carbon Capture Center in Alabama. What are the roadblocks that Evozyne faces in the ever- changing landscape of the business world? Science is unpredictable, and it's hard. Those two facts, plus the competitive nature of biotech businesses, make it tempting to rush products to market. There are notable examples of synthetic biology companies that gave in to that temptation, sold products that didn't perform as billed and subsequently failed.
  12. 12. Evozyne followed those stories closely, and our team is committed to doing things differently. Our highly pragmatic, design/built/test model requires us to repeatedly prove to ourselves, with objective data, that the technology performs as expected in real-world conditions. Evozyne will bring products to market when and if they are proven to a high level of certainty. Being first can be a disadvantage if you fail to meet market expectations. Protecting our reputation is a top priority for Evozyne, and that means making sure we've done the hard work to prove the performance of our technology platforms. Beyond reputation management, recruiting top scientific talent is a hurdle for many biotech companies. Fortunately, Evozyne has proven its ability to hire top talent, which we attribute to our pragmatic approach, the impact of the problems we're working to solve, and the financial health of our company. It helps that Chicago is a world-class city, with globally renowned universities and a thriving ecosystem that supports emerging biotech and pharma companies. The scientific talent we need to succeed wants to work here and, more important, is happy living here. How is your company adapting to market orientation? Nearly half of the world's disease burden will be addressed by biology in the next 20 years. With that in mind, we're pursuing life-changing treatments for patients and finding ways to improve life for patients with diseases that aren't currently treatable. There are more than 10,000 diseases for which no medicine exists, and we hope to be part of the solution for patients who lack options. On the sustainability side, we're working to address climate change with an on-site solution for carbon capture. We're uncovering new paths to replace harmful plastics and addressing global warming by making carbon capture a reality. Our goal is to build high-performance proteins, with exceptionally advanced functionality that makes what's possible a reality. They are designed to be consistent with the laws of nature and match the complex character of natural environments, enabling biology-based solutions that open our imagination to what's possible in solving some of society's most intractable problems. What is your approach to implementing innovative technologies? It's important to understand that the protein sequence
  13. 13. space is impossibly large—much larger than the number of atoms in the known universe—and no existing approach can comprehensively search it. Yet that's where we believe we'll find answers to the world's most pressing scientific questions. Our machine learning models help us find evolvable proteins from that vast space that can be engineered to meet real world challenges. More importantly, we learn from every sequence generated in the design process, not just from the ones that work. Evozyne generates genotype-phenotype mapping for every sequence generated, adding to our libraries and ability to find desired solutions faster. The design rules uncovered from these sequences help us simultaneously optimize several protein functions. That's a whole lot more efficient than optimizing one property at a time. This functional innovation forms our design philosophy, unlocking the natural potential of evolved proteins. How does your company provide a societal benefit? We're using science to solve some of the most complex problems our society faces. Think about it like this. Our platform is capable of creating molecules that surpass the current limits of performance. We can achieve targeted improvements in function that mirrors the capabilities of natural evolution. If nature is the world's best engineer, imagine what it can do if it's fast- forwarded by a few million years. What is the next chapter for Evozyne? Our focus is on developing technology platforms for therapeutics and sustainability. On the therapeutics side, the focus is on gene optimization, gene editing, and future- proofed antibodies. Gene replacement therapy requires better-than-wildtype performing genes to minimize dosing, maximize efficacy, and reduce immunogenicity. Existing gene therapies are not simultaneously optimized across all these dimensions. Furthermore, certain diseases require replacement of genes that are too large to fit into existing delivery technologies, rendering them inaccessible. Using our computational biology approach, we engineer transgenes with superior performance in activity, affinity, stability, and immunogenicity. In addition, Evozyne's technology enables miniaturization of the gene cassette, unlocking cures for previously inaccessible diseases. Gene editing with CRISPR-Cas nucleases has introduced new therapeutic modalities to treat a wide range of diseases. Yet the existing nucleases are not specific enough and can cause off-target editing, which means they edit the genome in areas that are not intended. By augmenting and redesigning the nucleases created by nature, Evozyne is developing a comprehensive library of highly specific Cas nucleases that can access most of the genome. This combination of accessibility and specificity will allow previously untreatable diseases to be cured safely and effectively with our enzymes. The Pandemic provided another complex problem that we hope to solve. We all know that as viruses mutate, they develop resistance to antibodies, rendering therapeutics ineffective. The problem treating viral infection is one of understanding the evolvability of the virus. Despite widespread research, current discovery tools have limited success in countering viral resistance. Using our ability to understand the constraints on viral evolution, Evozyne is developing an approach to generate future-proofed, broadly neutralizing antibodies. Our first application of this platform is a variant-resistant COVID-19 antibody. Evozyne's sustainability practice is focused on carbon capture and battery technology. Capturing carbon at the point of production has been inefficient and energy-intensive. Right now, it's too expensive to reduce emissions. While naturally occurring solutions can improve efficiency, they cannot withstand harsh industrial conditions and can't perform at high temperatures. Leveraging design rules encoded by nature, Evozyne is developing a highly efficient organic catalyst that remains stable in the required industrial conditions, making carbon capture at the point of production cost-effective.
  14. 14. October 2022 | 16 | www.insightssuccess.com
  15. 15. October 2022 | 17 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  16. 16. October 2022 | 18 | www.insightssuccess.com
  17. 17. October 2022 | 19 | www.insightssuccess.com
  18. 18. October 2022 | 20 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  19. 19. October 2022 | 21 | www.insightssuccess.com
  20. 20. October 2022 | 22 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  21. 21. October 2022 | 23 | www.insightssuccess.com
  22. 22. October 2022 | 26 | www.insightssuccess.com
  23. 23. October 2022 | 27 | www.insightssuccess.com
  24. 24. October 2022 | 28 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  25. 25. October 2022 | 29 | www.insightssuccess.com
  26. 26. October 2022 | 30 | www.insightssuccess.com
  27. 27. October 2022 | 31 | www.insightssuccess.com
  28. 28. October 2022 | 32 | www.insightssuccess.com
  29. 29. October 2022 | 33 | www.insightssuccess.com
  30. 30. October 2022 | 36 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  31. 31. October 2022 | 37 | www.insightssuccess.com
  32. 32. October 2022 | 38 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  33. 33. October 2022 | 39 | www.insightssuccess.com
  34. 34. October 2022 | 40 | www.insightssuccess.com The 10 Most Emerging Biotech Companies To Watch in 2022
  35. 35. October 2022 | 41 | www.insightssuccess.com

×